- RIUMA Principal
- Listar por autor
Listar por autor "Maguire, Thomas"
Mostrando ítems 1-2 de 2
-
Drug repurposing based on a quantum-inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2.
Jimenez-Guardeño, Jose Manuel; Ortega-Prieto, Ana María; Menéndez-Moreno, Borja; Maguire, Thomas; Richardson, Adam; Díaz-Hernández, Juan Ignacio; Díez- Pérez, Javier; Zuckerman, Mark; Cordero-Deline, Carlos; Malim, Michael H.; Martínez-Núñez, Rocío Teresa[et al.] (PLOS, 2022)The COVID-19 pandemic has accelerated the need to identify new antiviral therapeutics at pace, including through drug repurposing. We employed a Quadratic Unbounded Binary Optimization (QUBO) model, to search for compounds ... -
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
Dupont, Liane; Snell, Luke B; Graham, Carl; Seow, Jeffrey; Merrick, Blair; Lechmere, Thomas; Maguire, Thomas; Hallett, Sadie R.; Pickering, Suzanne; Charalampous, Themoula; Alcolea-Medina, Adela; Huettner, Isabella; Jimenez-Guardeño, Jose Manuel; Acors, Sam; Almeida, Nathalia; Cox, Daniel; Dickenson, Ruth; Galao, Rui Pedro; Kouphou, Neophytos; Lista, Maria Jose; Ortega-Prieto, Ana María; Wilson, Harry D; Winstone, Helena; Fairhead, Casssandra; Su, Jia Zhe; Nebbia, Gaia; Batra, Rahul; Neil, Stuart JD; Shankar-Hari, Manu; Edgeworth, Jonathan D; Malim, Michael H.; Doores, Katie J[et al.] (Nature Research, 2021)COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses ...